Artios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of the PARP inhibitor, Lynparza™, along with the scientific guidance of DDR pioneer, Dr. Graeme Smith, Artios has been able to make a scientific impact. However, in this episode, we will explore their financial impact, as CFO Abid Ansari details how Artios has been able survive and thrive in this challenging market environment.
Podden och tillhörande omslagsbild på den här sidan tillhör LifeSci Partners.com. Innehållet i podden är skapat av LifeSci Partners.com och inte av, eller tillsammans med, Poddtoppen.
